Abstract:Recombinant tissue plasminogen activator (rPA) has been used as a thrombolytic agent.However,considerable improvements have been done to prolong its plasma half-life (tl/2) and reduce its side effects,such as intracranial hemorrhage.Based on these improvements,a mutant of rPA,mrPA,was designed by mutating its PAⅠ-1 binding site to extend its t1/2.Furthermore,a fusion protein conjugating mrPA with NR3 was designed,which was a rAcAp5 mutant with a platelet GPⅡb/Ⅲa-binding RGD motif,to enhance the ability of targeted-thrombus and thrombolysis.The synthesized DNA sequences coding the two proteins were amplified by PCR,cloned into pET30a to construct recombinant plasmids pET30a-mrPA and pET30a-mrPA-NR3,and transformed into E.coli BL21 (DE3).The two proteins were expressed in inclusion bodies induced by isopropyl ｀-D-1-thiogalactopyranoside.After purified to qualified purity using one-step Ni affinity chromatography,the denatured proteins were refolded by dialysis.Their thrombolytic effects in vitro and in vivo were evaluated.In vitro 3.5 and 7 μmol/L of mrPA significantly reduced thrombus weight;1.75,3.5 and 7 μmol/L of mrPA-NR3 also significantly reduced the thrombus weight,and mrPA-NR3 displayed stronger thrombolytic effects than mrPA at 7 μmol/L.In vivo both mrPA and mrPA-NR3 showed significantly thrombolytic effect at 60-240 μmol/kg in thrombolytic model of inferior vena cava.Importantly,mrPA-NR3 exhibited more potent thrombolytic effect than both mrPA and rhM-tPA (positive control) at 240 μmol/kg.In addition,these two novel proteins did not increase bleeding time while they exerted thrombolytic effect.In conclusion,we engineered two novel proteins and proved that fusion protein had better thrombolytic effect than non-fusion protein,and the results suggest that dual thrombolytic mechanism or thrombus-target potentiated the thrombolytic effect of rPA and alleviated hemorrhage side reaction.This study may shed light on the development of novel thrombolytic agents with targeted thrombolysis and reduced side effects.

Construction and Biological Activities of Human Tpa Eukaryotic Expression Plasmid.

Construction of Eukaryotic Expression Plasmid Containing Tpa Genes and Its Expression in Transfected VSMCs

Experimental Study on Establishing Eukaryotic Expression Vector Pcdna3.1(+) TPA and Its Expressing Activity in Human Skin Fibroblists.

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Construction of the Prokaryotic Expression Vector of Human Tissue-Type Plasminogen Activator and Its Preliminary Expression in Escherichia coli

Retroviral Vector-Mediated Transfer and Expression of Human Tissue Plasminogen Activator Cdna in Bovine Brain Endothelial Cells

[Construction of Co-Expression Plasmid Containing Tpa and VEGF165 Genes and Its Expression in VSMCs].

Cloning and Expression of the Cdna Encoding Human Tissue Inhibitor of Metalloproteinase-3 and Its Inhibition on Angiogenesis

[Effects of Co-Expression Plasmid of Human Tpa and VEGF165 on the Proliferation of Vascular Cells and Fibrinolysis Activity].

Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli

Study on the Cloning and Expression of Human Fibrinogen α ,β, γ Gene

Study on the Cloning and Expression of Human Fibrinogen Α,β,γ Gene

Cloning and Expression of Human Fetal Cardiac Troponin T Isoform

Design, Preparation and Activity Evaluation of Novel Recombinant Thrombolytic Proteins

Construction and Expression in HUVEC of Eukaryotic Expressed Plasmid Vector Pcmv-(Kozak) TFPI

Construction of retroviral vector with tissue type plasminogen activator gene and culture of pure packaging cell line

A study on biological activity of co-expression plasmid of human tissue plasminogen activator and vascular endothelial growth factor 165

Cloning, Expression and Biological Characterization of Htfpi-2 Gene

Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug-delivery system

Active Expression of Human Tissue Plasminogen Activator (t-PA) c-DNA from Pulmonary Metastases in the Methylotrophic Yeast Pichia Pastoris KM71H Strain

[Study on inhibiting the intimal hyperplasia after rabbit artery injury by local transfection of tissue-type plasminogen activator gene].